Cipla To Sell Serum's New Flu Vaccine Nasovac In India
Photo Credit :
Drug maker Cipla said on Wednesday (27 May) that it has signed an agreement with Serum Institute of India, a global leader in the production of vaccines, to exclusively market the latter's new flu vaccine Nasovac-S in India.
Under this agreement, Serum will develop and manufacture the vaccine at its WHO approved facility in Pune, and Cipla will exclusively market it across India.
“We are extremely delighted to have entered into a strategic partnership with SII in India. This collaboration is aligned with our commitment to access to affordable healthcare and is a significant step towards making preventative healthcare accessible to a large number of Indians through Cipla’s strong countrywide salesforce,” said Cipla's managing director and global chief executive officer Subhanu Saxena in a Wednesday statement.
Cipla is also now exploring the possibility of extending this marketing tie-up to other markets in the world, where the company has a strong presence, as Serum has already initiated the approval process with the European Medicines Authority and a few other regulators.
Influenza occurs globally with an annual attack rate estimated at 5%–10% in adults and 20%– 30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. According to Cipla, the advantage of Nasovac-S vaccine is that it is administered through the nasal route and is therefore painless. "It also increases indirect protection through herd immunity and protects against drifted viruses," Cipla said.
Cipla is already marketing a range of other vaccines made by Serum in the global markets through an earlier signed marketing partnership and the influenza vaccine marketing in India is an extention of the existing relationship.